

Corporate Seminar

J Japanese Session / **E** English Session

10-Oct (Fri) 12:40–13:25

JLS1-2 Pathophysiology and Treatment of Chronic GVHD

【No.2 Kobe Portopia Hotel Main Building B1F Kairaku 1】

- Chair** Toshihiro Miyamoto (Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University)
- Speaker** Daigo Hashimoto (Hokkaido University Faculty of Medicine, Department of Hematology)
- Sponsor** Meiji Seika Pharma Co., Ltd.

ELS1-3 Treatment strategy and safety management of Talquetamab in Triple-Class Exposed multiple myeloma.

【No.3 Kobe Portopia Hotel Main Building B1F Kairaku 3】

- Chair** Shinsuke Iida (Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan)
- Speaker** Ajai Chari (Clinical Medicine, University of California at San Francisco)
- Sponsor** Johnson & Johnson

JLS1-4 Underlying Congenital Immunodeficiencies in Hematologic Diseases

Live Recording On-demand

【No.4 Kobe Portopia Hotel Main Building B1F Waraku】

- Chair** Masafumi Onodera (Graduate School of Engineering, The University of Osaka)
- Speaker** Hirokazu Kanegane (Department of Child Health and Development, Institute of Science Tokyo)
- Sponsor** Pharming Group N.V.

ELS1-9 Bispecific antibodies in the treatment of relapsed or refractory follicular lymphoma

【No.9 Kobe International Conference Center 1F Main Hall】

- Chair** Dai Maruyama (Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)
- Speaker** Lorenzo Falchi (Memorial Sloan Kettering Cancer Center, USA)
- Sponsor** CHUGAI PHARMACEUTICAL CO.,LTD.

■LS1-10

[No.10 Kobe International Conference Center 3F International Conference Room 301]

Chair Shin-ichi Fuchida (Department of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center)

Elranatamab for Relapsed and Refractory Multiple Myeloma

Speaker Kazutaka Sunami (Department of Hematology, National Hospital Organization Okayama Medical Center)

Treatment strategy for TCE -Based on experience with Elranatamab-

Speaker Tadao Ishida (Myeloma and AL Amyloidosis Unit, Japanese Red Cross Medical Center)

Sponsor Pfizer Japan Inc.

■LS1-11 Reconstructing ITP treatment strategies from an immunological perspective — an approach based on TPO-receptor agonists

[No.11 Kobe International Conference Center 4F 401+402]

Chair Yoshiaki Tomiyama (Uegahara Hospital)

Speaker Tomoki Ito (First Department of Internal Medicine, Kansai Medical University)

Sponsor Sobi Japan

■LS1-12 Antibody Engineering for Targeted Therapy

[No.12 Kobe International Conference Center 4F 403]

Chair Youko Suehiro (Department of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center)

Speaker Kouhei Tsumoto (Department of Bioengineering, School of Engineering, The University of Tokyo)

Sponsor Mitsubishi Tanabe Pharma Corporation

■LS1-13 From Bench to Bedside: The Emergence and Future Perspectives of Anti-TFPI Rebalancing Therapy

[No.13 Kobe International Conference Center 5F 501]

Chair Teruto Hashiguchi (Department of Laboratory and Vascular Medicine, Kagoshima University Graduate school of Medical and Dental Sciences)

Speaker Keiji Nogami (Department of Pediatrics, Nara Medical University)

Sponsor Novo Nordisk Pharma Ltd.

■LS1-14 Novel diagnostic and therapeutic approaches for disease with eosinophilia

[No.14 Kobe International Conference Center 5F 502]

Chair Mineo Kurokawa (Department of Hematology and Oncology, The University of Tokyo Hospital)

Speaker Hidehiro Itogawa (Department of Hematology and Cell Therapy, Nagasaki University Hospital)

Sponsor Incyte Biosciences Japan G.K.

■LS1-15 COVID-19, Treatment Strategies for Resistant Gram-Negative Bacterial Infections Update

[No.15 Kobe International Conference Center 5F 504+505]

Chair Noriko Fukuhara (Department of Hematology, Tohoku University Graduate School of Medicine)

Persistent SARS-CoV-2 infection in Patients with Hematologic Malignancies: Clinical Challenges and Updated Therapeutic Strategies

Speaker Kazuaki Fukushima (Department of Infection Control & Prevention, Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital)

Antimicrobial-resistant Gram-negative infections in patients with hematological disorders

Speaker Hideki Araoka (Department of Infectious Diseases, Department of Clinical Laboratory, Toranomon Hospital)

Sponsor Shionogi & Co.,Ltd.

■LS1-16 Current Evidence and Emerging Therapies in Relapsed/Refractory PTCL: Present Status and Novel Treatment Options

[No.16 Kobe International Exhibition Hall No.2 Building 3F 3A Meeting Room]

Chair Tsuyoshi Muta (Hematology - Japanese Red Cross Society-Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital)

Speaker Hirotohi Kamata (Department of Hematology, Kitasato University School of Medicine)

Sponsor DAIICHI SANKYO COMPANY, LIMITED.

■LS1-17 Optimization of Therapeutic Strategies with Acalabrutinib

[No.17 Kobe International Exhibition Hall No.2 Building 2F 2A Meeting Room]

Chair Hirokazu Nagai (NHO Nagoya Medical Center)

Speaker Kana Miyazaki (Department of Hematology and Oncology, Mie University Graduate School of Medicine)

Sponsor AstraZeneca K.K.

■LS1-18 How to use the Sarclisa® -From basic and clinical standpoints-

[No.18 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall B]

Chair Chihiro Shimazaki (JCHO Kyoto Kuramaguchi Medical Center)

Speaker Keichiro Mihara (Dept. Translational Research, Int. Center for Cell and Gene Therapy, Cellular Immunotherapies for Cancer, Graduate School of Med. Fujita Health University)

Speaker Takashi Ikeda (Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center)

Sponsor Sanofi K.K.

**■LS1-19 A New Option for BCMA-Targeted Therapeutics
~Belantamab Mafodotin as a Second-line Treatment~**

[No.19 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall A]

- Chair** Yoichi Imai (Department of Internal Medicine (Hematology and Oncology), Dokkyo Medical University)
Speaker Kazuhito Suzuki (Department of Hematology, Tokyo Jikeikai Medical University)
Sponsor GlaxoSmithKline K.K.

11-Oct (Sat) 11 : 30—12 : 15

■LS2-2 FLT3 inhibition in AML: current strategies

[No.2 Kobe Portopia Hotel Main Building B1F Kairaku 1]

- Chair** Kenichi Matsuoka (Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School)
Speaker Mark Levis (Johns Hopkins Sidney Kimmel Comprehensive Cancer Center)
Sponsor Astellas Pharma Inc.

■LS2-3 Defining positioning of CAR T-Cell Therapy in the Management of DLBCL, Enhancing Treatment Strategies Based on Real-World Evidence

[No.3 Kobe Portopia Hotel Main Building B1F Kairaku 3]

- Chair** Nobuharu Fujii (Division of Transfusion and Cell therapy, Okayama University Hospital)
Current Landscape of CAR T-Cell Therapy: Real-World Data and Clinical Experience Informing Patient Selection and Treatment Decisions
Speaker Yu Yagi (Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital)
Current DLBCL treatment strategy in US – What RWE can teach us
Speaker David Miklos (Blood and Marrow Transplantation and Cellular Therapy, Stanford University)
Sponsor Gilead Sciences K.K.

■LS2-4 Unveiling the True Value of Carfilzomib in the Immunotherapy Era

[No.4 Kobe Portopia Hotel Main Building B1F Waraku]

- Chair** Hideto Tamura (Division of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center)
Unveiling the Hidden Potential of Carfilzomib from a basic research perspective: The Dual Aspects of Suppression and Modulation
Speaker Kentaro Serizawa (Department of Hematology and Rheumatology, Kindai University Hospital)
The Light and Shadow of Carfilzomib — A Powerful Sword in Clinical Practice
Speaker Teruhito Takakuwa (Department of Hematology, Wakakusa Daiichi Hospital)
Sponsor ONO PHARMACEUTICAL CO., LTD.

LS2-5 Treatment and prognosis of ATL skin lesions

[No.5 Kobe Portopia Hotel South Wing B1F Sapphire]

Chairs Kaoru Uchimaru (Professor emeritus, The University of Tokyo)
Kenji Ishitsuka (Kagoshima University, Department of Hematology and Rheumatology)

Efficacy and safety of Targretin® for ATL skin lesions

Speaker Kentaro Yonekura (Imamura General Hospital, Department of Dermatology)

Recent topics on diagnosis and prognosis predictors for ATL

Speaker Shigeo Fuji (Osaka International Cancer Institute, Department of Hematology)

Sponsor Minophagen Pharmaceutical Co., Ltd.

LS2-6 Pathology and treatment for elderly/frail patients with myeloma: aging science in myeloma

[No.6 Kobe Portopia Hotel South Wing B1F Topaz]

Chair Hirohiko Shibayama (Department of Hematology, NHO Osaka National Hospital)

Speaker Masahiro Abe (Department of Hematology, Kawashima Hospital)

Sponsor Takeda Pharmaceutical Company Limited

LS2-7 Molecular pathogenesis and clinical significance of follicular lymphoma

~ Potential of personalised medicine targeting the epigenome ~

[No.7 Kobe Portopia Hotel South Wing B1F Emerald]

Chair Momoko Nishikori (Kyoto University Graduate School of Medicine, Department of Human Health Sciences)

Speaker Daisuke Ennishi (Department of Haematology and Oncology, Centre for the Comprehensive Promotion of Genomic Medicine, Okayama University Hospital)

Sponsor Eisai Co., Ltd.

LS2-8 Clinical experience of Ropeginterferon Alfa-2b for PV Treatment

[No.8 Kobe Portopia Hotel South Wing B1F Diamond]

Chair Daigo Akahane (Department of Hematology, Tokyo Medical University)

Speaker Prithviraj Bose (Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX)

Sponsor PharmaEssentia Japan

■LS2-9 What is the optimal strategy for newly diagnosed chronic-phase CML?

[No.9 Kobe International Conference Center 1F Main Hall]

- Chair** Shinya Kimura (Div Hematology, Respiratory Medicine and Oncology, Saga University)
- Speaker** Takaaki Ono (Department of Transfusion and Cell-Therapy, Hamamatsu University School of Medicine)
- Sponsor** Novartis Pharma K.K.

■LS2-10 A New Era in Anemia Management for lower risk MDS: "luspatерcept a paradigm shift"

[No.10 Kobe International Conference Center 3F International Conference Room 301]

- Chair** Seiji Ogawa (Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University)
- Speaker** Rami S. Komrokji (Department of Malignant Hematology, Moffitt Cancer Center)
- Sponsor** Bristol Myers Squibb K.K.

■LS2-11 Efficacy and safety of fostamatinib for immune thrombocytopenia in our hospital

[No.11 Kobe International Conference Center 4F 401+402]

- Chair** Yoshinobu Maeda (Department of Hematology, Oncology and Respiratory, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences)
- Speaker** Toshiki Yamada (Department of Hematology, Gifu Prefectural General Medical Center)
- Sponsor** KISSEI PHARMACEUTICAL CO., LTD.

■LS2-12 Biology-driven treatment strategy for chronic graft versus host disease

[No.12 Kobe International Conference Center 4F 403]

- Chair** Takehiko Mori (Department of Hematology, Institute of Science Tokyo)
- Speaker** Tomomi Toubai (Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Clinical Research and Trials Center/Hematology Division)
- Sponsor** Therakos Japan K.K.

■LS2-13 Cold Agglutinin Disease: The Various Pathologies and The Role of Anticomplement Drug

[No.13 Kobe International Conference Center 5F 501]

- Chair** Takahiro Suzuki (Department of Hematology, Kitasato University School of Medicine)
- Speaker** Hideho Wada (Department of General Medicine, Kawasaki Medical School)
- Sponsor** Recordati Rare Diseases Japan K.K.

■LS2-14 A review of the roles of IMiDs and anti-RANKL antibody in the treatment of multiple myeloma

[No.14 Kobe International Conference Center 5F 502]

- Chair** Shingo Yano (Oncology and Hematology, THE JIKEI UNIVERSITY SCHOOL OF MEDICINE)
Speaker Kota Sato (Department of Hematology, Japanese Red Cross Medical Center)
Sponsor Fuji Pharma Co., Ltd.

■LS2-15 Treatment strategies for follicular lymphoma

[No.15 Kobe International Conference Center 5F 504+505]

- Chair** Satoshi Ichikawa (Tohoku Medical and Pharmaceutical University, Division of Hematology and Rheumatology)
Speaker Ryoko Fukushima (Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Daisan Hospital)
Sponsor SymBio Pharmaceuticals Ltd.

■LS2-16 Treatment strategy for CLL and clinical positioning of zanubrutinib

[No.16 Kobe International Exhibition Hall No.2 Building 3F 3A Meeting Room]

- Chair** Koji Nagafuji (Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine)
Speaker Takahiro Kumode (Kindai University Hematology and Rheumatology)
Sponsor BeOne Medicines Japan

■LS2-17 Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024

[No.17 Kobe International Exhibition Hall No.2 Building 2F 2A Meeting Room]

- Chair** Yasuhisa Yokoyama (Department of Hematology/Transfusion Medicine and Cell Therapy, National Center for Global Health and Medicine, Japan Institute for Health Security)
Speaker Yoshinobu Seki (Department of Hematology, Niigata University Medical and Dental Hospital/Niigata Cancer Center Hospital)
Sponsor Asahi Kasei Pharma Corporation

■LS2-18 Mantle Cell Lymphoma and Venclexta ~From MoA to Clinical Practice~

[No.18 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall B]

Chairs Takayuki Tabayashi (Department of Hematology, Saitama Medical Center, Saitama Medical University)
Yusuke Furukawa (Department of Medical Education, Teikyo University of Science)

Molecular Basis of Efficacy and Adverse Effects of Venetoclax Combination Therapy in MCL

Speaker Yusuke Furukawa (Department of Medical Education, Teikyo University of Science)

Venetoclax treatment strategy for the latest MCL treatment

Speaker Takayuki Tabayashi (Department of Hematology, Saitama Medical Center, Saitama Medical University)

Sponsor AbbVie GK

12-Oct (Sun) 12:00–12:45

■LS3-2 Optimal combination therapy for ITP using biomarkers

[No.2 Kobe Portopia Hotel Main Building B1F Kairaku 1]

Chair Eriko Morishita (Department of Clinical Laboratory Science, Division of Health Sciences, Kanazawa University)

Immature platelets indicate optimal strategy for FcRn inhibitors

Speaker Fumiya Wada (Department of Hematology, Kyoto University Hospital)

Therapeutic Potential of the FcRn Inhibitor Efgartigimod –Exploring the Direction of Optimal Combination Therapy from the Perspective of IPF–

Speaker Kaichi Nishiwaki (Department of Oncology and Hematology, Jikei University Kashiwa Hospital)

Sponsor argenx Japan K.K.

■LS3-3 Optimizing Treatment Strategies for Primary CNS Lymphoma Through Collaboration With Neurosurgery

[No.3 Kobe Portopia Hotel Main Building B1F Kairaku 3]

Chair Yasufumi Masaki (Department of Hematology & Immunology, Kanazawa Medical University)

Speaker Yuma Tada (Department of Hematology, Osaka International Cancer Institute)

Sponsor Sumitomo Pharma Co., Ltd.

■LS3-4 Time Toxicity and Febrile Neutropenia Management in Malignant Lymphoma

[No.4 Kobe Portopia Hotel Main Building B1F Waraku]

Chair Ken Omachi (Department of Hematology Oncology, Tokai University Hospital)

Speaker Nobuhiko Nakamura (Department of Hematology and Infectious Disease, Gifu University Hospital)

Sponsor Kyowa Kirin Co., Ltd.

LS3-5 Prevention of Invasive Fungal Infections in Hematologic Patients in the Era of Novel Anticancer Agents: Interpretation and Clinical Implementation of the Latest European Conference on Infections in Leukemia (ECIL) Guidelines

[No.5 Kobe Portopia Hotel South Wing B1F Sapphire]

- Chair** Keisuke Kataoka (Division of Hematology, Department of Medicine, Keio University School of Medicine / Division of Molecular Oncology, National Cancer Center Research Institute)
- Speaker** Akinao Okamoto (Department of Hematology, Fujita Health University)
- Sponsor** MSD K.K.

LS3-6 Advances in Ph+ Leukemia: Evolving Strategies in Diagnosis and Treatment

[No.6 Kobe Portopia Hotel South Wing B1F Topaz]

- Chair** Hitoshi Hanamoto (Department of Hematology, Kindai Nara Hospital)
- Speaker** Koji Sasaki (Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston TX, U.S.A.)
- Sponsor** Otsuka Pharmaceutical Co., Ltd.

LS3-7 Reconsidering HD-MTX Therapy in the Treatment of CNS Lymphoma: A Novel Approach to Delayed Methotrexate Elimination with Glucarpidase

[No.7 Kobe Portopia Hotel South Wing B1F Emerald]

- Chair** Keita Kirito (Department of Hematology and Oncology, University of Yamanashi)
- Speaker** Nobuhiko Yamauchi (Department of Hematology Oncology, Cancer Institute Hospital of JFCR)
- Sponsor** OHARA Pharmaceutical Co., Ltd.

LS3-8 From prognostication to precision in acute myeloid leukemia, the case of FLT3-ITD

[No.8 Kobe Portopia Hotel South Wing B1F Diamond]

- Chair** Yosuke Minami (National Cancer Center East Hospital)
- Speaker** Christopher Hourigan (Verginia Tech. Cancer Research Center)
- Sponsor** Invivoscribe/LabPMM GK

**■LS3-9 Lead Treatment of Multiple Myeloma with Daratumumab
~Treatment choice of TIE~**

[No.9 Kobe International Conference Center 1F Main Hall]

Chair Hiroshi Handa (Department of Hematology, Gunma University
Graduate School of Medicine)

**The merging role of quadruplet regimen for transplant-ineligible newly
diagnosed multiple myeloma**

Speaker Nobuhiro Tsukada (Department of Hematology Japanese Red Cross
Medical Center)

**Optimizing First-Line Treatment Strategies for Transplant-Ineligible Myeloma
Patients**

Speaker Yuichi Horigome (Department of Hematology, Kitasato University
Hospital)

Sponsor Johnson & Johnson

**■LS3-10 Challenges and Future Perspectives in CML therapy : Treatment
Strategies Balancing Adherence and QoL**

[No.10 Kobe International Conference Center 3F International Conference Room 301]

Chair Noriyoshi Iriyama (Department of Hematology and Rheumatology,
National Hospital Organization Saitama Hospital)

Speaker Tomoiku Takaku (Division of Hematology, Saitama Medical
University)

Sponsor Novartis Pharma K.K. Medical Affairs

**■LS3-11 Iron: The Essence of Life
~From the Origins of Life to Iron Deficiency Anemia~**

[No.11 Kobe International Conference Center 4F 401+402]

Chair Hideo Harigae (Department of Hematology, Tohoku University
Graduate School of Medicine)

Speaker Norio Komatsu (Department of Hematology, Juntendo University
School of Medicine)

Sponsor Medical Affairs Department, Torii Pharmaceutical Co., Ltd.

■LS3-12 To achieve zero bleeding deaths~The Expected Role of Byclot~

[No.12 Kobe International Conference Center 4F 403]

Chair Kagehiro Amano (Department of Laboratory Medicine, Tokyo Medical
University Hospital)

Speaker Nobuaki Suzuki (Department of Transfusion Medicine, Nagoya
University Hospital)

Sponsor KM Biologics Co., Ltd./Japan Blood Products Organization

■LS3-13 Diagnosis of PNH in Aplastic Anemia

[No.13 Kobe International Conference Center 5F 501]

- Chair** Shikiko Ueno (Department of Transfusion Medicine and Cell Therapy, Kumamoto University Hospital)
- Speaker** Mitsuhiro Itagaki (Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital)
- Sponsor** Alexion Pharma GK

■LS3-14 Long-term follow-up after hematopoietic stem cell transplantation – Focusing on vaccination, prevention of second primary malignancy, chronic GVHD treatment, and management of hypogammaglobulinemia –

[No.14 Kobe International Conference Center 5F 502]

- Chair** Satoshi Yoshihara (Department of Respiratory Medicine and Hematology, Hyogo Medical University)
- Speaker** Junya Kanda (Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan)
- Sponsor** CSL Behring K.K.

■LS3-15 With a “big” help from clinical flow cytometry to advance your hematology

[No.15 Kobe International Conference Center 5F 504+505]

- Chair** Naoki Hosen (Hematology and Oncology, Osaka University Graduate School of Medicine)
- Speaker** Takero Shindo (Division of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University)
- Sponsor** Nippon Becton Dickinson Co., Ltd.

■LS3-16 Current approaches for R/R DLBCL – Appropriate timing for immune cell therapy –

[No.16 Kobe International Exhibition Hall No.2 Building 3F 3A Meeting Room]

- Chair** Yasuhito Terui (Department of Hematology, Saitama Medical University Hospital)
- Speaker** Hideki Goto (Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital)
- Sponsor** Genmab K.K. / AbbVie GK

■LS3-17 Blinatumomab Therapy and Tumor Immunity in Relapsed/Refractory Acute Lymphoblastic Leukemia

[No.17 Kobe International Exhibition Hall No.2 Building 2F 2A Meeting Room]

- Chair** Masashi Sawa (Department of Hematology and Oncology, Anjo Kosei Hospital)
- Speaker** Tatsuro Jo (Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital)
- Sponsor** Amgen K.K./Astellas Pharma Inc.

**■LS3-18 State-of-the-Art therapeutics in lymphoid tumors:
the role of non-covalent BTK inhibitors**

[No.18 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall B]

Chair Yasushi Takamatsu (Division of Medical Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University)

Speaker Kensuke Kojima (Department of Hematology, Kochi Medical School, Kochi University)

Sponsor Nippon Shinyaku Co., Ltd.

10-Oct (Fri) 17 : 40—18 : 25

■ES1-2 Clinical Use of FLT3 Inhibitors in AML Across the Disease Span

[No.2 Kobe Portopia Hotel Main Building B1F Kairaku 1]

Chair Yasushi Miyazaki (Department of Hematology, Atomic Bomb Disease, Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University)

Speaker Catherine Smith (Division of Hematology/Oncology, Department of Medicine, UCSF)

Sponsor Daiichi Sankyo Medical Affairs

■ES1-3

[No.3 Kobe Portopia Hotel Main Building B1F Kairaku 3]

Chair Akiyoshi Takami (Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine)

Successful treatment of rapid use of Caplacizumab for TTP in clinical practice

Speaker Takafumi Tsushima (Department of Hematology and Oncology, Japanese Red Cross Narita Hospital)

Treatment strategies for TTP focusing on organ protection

Speaker Kazuya Sakai (Department of Blood Transfusion Medicine, Nara Medical University)

Sponsor Sanofi K.K.

■ES1-4 PNH Treatment: Up to Date

[No.4 Kobe Portopia Hotel Main Building B1F Waraku]

Chair Yasutaka Ueda (Department of Hematology and Oncology, The University of Osaka Graduate School of Medicine)

New Perspectives in the Management of PNH: A Comprehensive Understanding Including Bone Marrow Failure-Type PNH

Speaker Kohei Hosokawa (Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan)

Clinical experience with pegcetacoplan considering comorbidities

Speaker Satoshi Yamamoto (Department of Hematology, Sapporo City General Hospital)

Sponsor Asahi Kasei Pharma Corporation

**ES1-9 High-Risk AML Treatment with CPX-351:
Hope for Cure and Challenges in Patient Selection & Management**
[No.9 Kobe International Conference Center 1F Main Hall]

Chair Koichi Akashi (Kyusyu University)
Speaker Naoko Hosono (Department of Blood Transfusion, University of Fukui Hospital)
Sponsor Nippon Shinyaku Co., Ltd.

ES1-10 Treatment strategy for CML in 2025 through looking back on the Bosulif 10 years
[No.10 Kobe International Conference Center 3F International Conference Room 301]

Chair Chiaki Nakaseko (Department of Hematology, International University of Health and Welfare)
Speaker Hiroshi Ureshino (Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University)
Sponsor Pfizer Japan Inc.

ES1-11 Tackling Acquired Hemophilia A: Hemostasis-Thrombosis Balance and Emerging Therapeutic Options
[No.11 Kobe International Conference Center 4F 401+402]

Chair Yoshiyuki Ogawa (Division of Blood Transfusion, Gunma University Hospital)
Speaker Masato Bingo (Department of Laboratory Medicine, Tokyo Medical University)
Sponsor Takeda Pharmaceutical Company Limited

ES1-12 Molecular Biological Approaches to Unraveling Malignant Lymphoma: Pathogenesis and Treatment Strategies
[No.12 Kobe International Conference Center 4F 403]

Chair Akihiro Tomita (Department of Hematology, Fujita Health University)
Speaker Tomohiro Aoki (Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Faculty of Medicine, University of Toronto)
Sponsor CHUGAI PHARMACEUTICAL CO.,LTD.

**ES1-13 The Next Step in CML Treatment: Integrating QoL into Clinical Decision-Making
-Insights from a Global Patient Advocate and CML Expert-**

[No.13 Kobe International Conference Center 5F 501]

Chair Chikashi Yoshida (National Hospital Organization Mito Medical Center)

Understanding QoL for patients living with CML and why it matters

Speaker Lisa Machado (The Canadian CML Network)

Considerations on the importance of tolerability and shared decision making in the continued treatment of CML

Speaker Eri Matsuki (Keio University School of Medicine, Department of Medicine, Division of Hematology)

Sponsor Novartis Pharma K.K.

ES1-14 Treatment Strategies for Waldenström's Macroglobulinemia/ Lymphoplasmacytic Lymphoma (WM/LPL): Considerations for Optimal Therapy Based on Real-World Clinical Practice

[No.14 Kobe International Conference Center 5F 502]

Chair Koji Izutsu (Department of Hematology, National Cancer Center Hospital)

Speaker Kohei Okada (Department of Hematology, Sapporo Hokuyu Hospital)

Sponsor ONO PHARMACEUTICAL CO., LTD.

ES1-15 Management of invasive fungal infection among patients with hematologic disorders.

[No.15 Kobe International Conference Center 5F 504+505]

Chair Shuichi Taniguchi (Hamanomachi Hospital)

Speaker Yasuo Mori (Department of Hematology, Oncology & Cardiovascular Medicine, Kyushu University Hospital)

Sponsor Sumitomo Pharma Co.,Ltd.

ES1-16 Latest treatments for T/NK cell lymphoma

[No.16 Kobe International Exhibition Hall No.2 Building 3F 3A Meeting Room]

Chair Motoko Yamaguchi (Department of Hematological Malignance, Mie University Graduate School of Medicine)

Speaker Shinichi Makita (Department of Hematology National Cancer Center Hospital)

Sponsor CHUGAI PHARMACEUTICAL CO.,LTD.

ES1-17 Deepening Understanding of Talquetamab from Basic Research and an Approach to the Management of Relapsed and Refractory Multiple Myeloma

[No.17 Kobe International Exhibition Hall No.2 Building 2F 2A Meeting Room]

Chair Kenshi Suzuki (Department of Hematology Myeloma and Amyloidosis Center, Japanese Red Cross Medical Center)

The Structure and Mode of Action of Talquetamab in light of the Trends in Bispecific Antibody Development

Speaker Kohei Tsumoto (Department of Bioengineering, School of Engineering, The University of Tokyo)

A New Option for the Management of Relapsed and Refractory Multiple Myeloma: The Significance of Talquetamab Therapy

Speaker Shigeki Ito (Hematology & Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine)

Sponsor Medical Affairs Division, Johnson & Johnson

ES1-18 Frontline Approaches in the Treatment of Relapsed/Refractory Follicular Lymphoma

[No.18 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall B]

Chair Jun Ando (Division of Cell Therapy and Blood Transfusion Medicine, Department of Hematology, Juntendo University Faculty of Medicine)

Recent advances in treatment for follicular lymphoma –Potential of CAR-T cell therapy–

Speaker Daisuke Kaji (Department of Hematology, Toranomon Hospital)

Second-Line Therapy for Follicular Lymphoma: Exploring the Role of CAR-T and Beyond

Speaker Kotaro Miyao (Department of Hematology and Oncology, Anjo Kosei Hospital)

Sponsor Bristol Myers Squibb K.K.

ES1-19 New treatment strategies for myelofibrosis

[No.19 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall A]

Chair Akihiko Goto (Center for Hematologic Intractable Diseases, Nerima Hikarigaoka Hospital)

Speaker Yuka Sugimoto (Department of Hematology and Oncology, Mie University Graduate School of Medicine)

Sponsor GlaxoSmithKline K.K.

11-Oct (Sat) 17:10–17:55

ES2-2 Killing Two Birds with One CANDY!

– A New Era of PNH Management with Oral Iptacopan Monotherapy

[No.2 Kobe Portopia Hotel Main Building B1F Kairaku 1]

Chair Jun-ichi Nishimura (Department of Hematology and Oncology,
The University of Osaka Graduate School of Medicine)

Speaker Toshio Kitawaki (Department of Hematology, Kyoto University
Hospital)

Sponsor Novartis Pharma K.K.

ES2-3 Optimizing Strategy in R/R DLBCL

[No.3 Kobe Portopia Hotel Main Building B1F Kairaku 3]

Chair Miki Ando (Department of Hematology, Juntendo University Faculty
of Medicine)

Optimizing management of relapsed/refractory diffuse large B-cell lymphoma

Speaker Jeremy Abramson (Harvard Medical School/Center for Lymphoma,
Massachusetts General Hospital)

Sponsor Bristol Myers Squibb K.K.

ES2-4 Therapeutic Strategies for Relapsed or Refractory Acute

Lymphoblastic Leukemia: Optimizing the Use of Immunotherapy

[No.4 Kobe Portopia Hotel Main Building B1F Waraku]

Chair Shuichi Ota (Department of Hematology, Sapporo Hokuyu Hospital)

Speaker Kentaro Fukushima (Department of Chemotherapy, The University of
Osaka Hospital)

Sponsor Pfizer Japan Inc.

ES2-5 Pros and Cons of proximal complement therapy for PNH

[No.5 Kobe Portopia Hotel South Wing B1F Sapphire]

Chair Yuzuru Kanakura (Sumitomo Hospital)

Speaker Tatsuya Kawaguchi (Department of Medical Technology, Faculty of
Health Sciences, Kumamoto Health Science University)

Sponsor Sobi Japan / Asahi Kasei Pharma Corporation

ES2-6 Treatment Strategies for Follicular Lymphoma

[No.6 Kobe Portopia Hotel South Wing B1F Topaz]

Chair Koji Kato (Kyushu University Graduate School of Medical Sciences,
Department of Medicine and Biosystemic Science)

Speaker Shigeru Kusumoto (Aichi Cancer Center)

Sponsor CHUGAI PHARMACEUTICAL CO.,LTD./Nippon Shinyaku Co., Ltd.

ES2-7 The significance and clinical experience of subcutaneous immunoglobulin replacement therapy for secondary hypogammaglobulinemia

[No.7 Kobe Portopia Hotel South Wing B1F Emerald]

- Chair** Kazunori Imada (Department of Hematology, Japanese Red Cross Osaka Hospital)
- Speaker** Yoshinori Hashimoto (Department of Hematology, Tottori Prefectural Central Hospital)
- Sponsor** Takeda Pharmaceutical Company Limited

ES2-8 Molecular Signatures in Aggressive Lymphoma and their Clinical Implications

[No.8 Kobe Portopia Hotel South Wing B1F Diamond]

- Chair** Eisei Kondo (Department of Hematology, Kawasaki medical school)
- Speaker** Björn Chapuy (Charite, University Medical Center Berlin und Berlin Institute of Health)
- Sponsor** ONO PHARMACEUTICAL CO., LTD.

ES2-9 Treatment Strategies for Unfit AML: Evolving Standards and New Therapeutic Options

[No.9 Kobe International Conference Center 1F Main Hall]

- Chair** Itaru Matsumura (Kindai University Faculty of Medicine)
- Speaker** Hartmut Döhner (University Hospital Ulm)
- Sponsor** Nihon Servier Co., Ltd.

ES2-10 The optimal sequences of BCMA-targeting therapy for relapse/refractory multiple myeloma

[No.10 Kobe International Conference Center 3F International Conference Room 301]

- Chair** Shuji Ozaki (Department of Hematology, Tokushima Prefectural Central Hospital)
- Speaker** Thomas G. Martin (UCSF Helen Diller Family Comprehensive Cancer Center)
- Sponsor** GlaxoSmithKline K.K.

ES2-11 Initial Treatment for Patients with Adult T-cell Leukemia-Lymphoma (ATL)

[No.11 Kobe International Conference Center 4F 401+402]

- Chair** Takuya Fukushima (Department of Health Sciences, Faculty of Medicine, University of the Ryukyus)
- Speaker** Masahito Tokunaga (Department of Hematology, Imamura General Hospital)
- Sponsor** Takeda Pharmaceutical Company Limited

ES2-12 Update on Strategies for CMV Infection Following Allogeneic Hematopoietic Stem Cell Transplantation

[No.12 Kobe International Conference Center 4F 403]

- Chair** Noriko Doki (Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital)
Speaker Junichi Sugita (Department of Hematology, Sapporo Hokuyu Hospital)
Sponsor MSD K.K.

ES2-13 Myelofibrosis Treatment: Ten Years Since the Introduction of JAK2 Inhibitors

[No.13 Kobe International Conference Center 5F 501]

- Chair** Hirohisa Nakamae (Department of Hematology, Osaka Metropolitan University Graduate School of Medicine)
Speaker Katsuto Takenaka (Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine)
Sponsor Novartis Pharma K.K.

ES2-14 Diagnostic approach to isolated thrombocytopenia

[No.14 Kobe International Conference Center 5F 502]

- Chair** Takaaki Hato (Japanese Red Cross Ehime Blood Center)
Speaker Kenji Yokoyama (Department of Hematology and Oncology, Tokai University Hachioji Hospital)
Sponsor Sanofi Rare Blood Disorders Medical

ES2-15 Optimizing Aplastic Anemia Treatment Through Clinical Trial Evidence

[No.15 Kobe International Conference Center 5F 504+505]

- Chair** Hirohito Yamazaki (Division of Medical Safety, Kanazawa University Hospital)
Speaker Ken Ishiyama (Department of Hematology, National Center for Global Health and Medicine)
Sponsor Kyowa Kirin Co., Ltd.

ES2-16 Up-to-Date Treatment Strategies for Elderly Patients with AML

[No.16 Kobe International Exhibition Hall No.2 Building 3F 3A Meeting Room]

- Chair** Takahiro Yamauchi (University of Fukui Faculty of Medical Sciences Division of Medicine General Medicine, Hematology and Oncology)
Tips for continuing Ven + AZA treatment that can be used from tomorrow
Speaker Goichi Yoshimoto (Saga-ken Medical Centre Koseikan Hematology)
Sponsor AbbVie GK

ES2-17 Evolving treatment strategy of Mantle cell lymphoma

[No.17 Kobe International Exhibition Hall No.2 Building 2F 2A Meeting Room]

Chair Hiro Tatetsu (Department of Hematology, Rheumatology, and Infectious diseases, Kumamoto University Hospital)

Next Steps in MCL Management: BTK Meets BCL2 in a New Era of Combination Therapy

Speaker Suguru Fukuhara (Department of Hematology, National Cancer Center Hospital)

Treatment experience with the combination therapy of Venetoclax and Ibrutinib for MCL

Speaker Satoshi Ito (Division of Hematology, Yamagata University Hospital)

Sponsor Johnson & Johnson

ES2-18 Genetic Panel Testing:

Opening New Frontiers in Hematologic Malignancy Care

[No.18 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall B]

Chair Akifumi Takaori-Kondo (Department of Hematology, Graduate School of Medicine, Kyoto University)

Speaker Motohiro Kato (Department of Pediatrics, The University of Tokyo Hospital)

Sponsor Otsuka Pharmaceutical Co., Ltd.

11-Oct (Sat) 7:30–8:15

MS2-2 Controlling B Cells with T Cells

[No.2 Kobe Portopia Hotel Main Building B1F Kairaku 1]

Chair Norimitsu Kadowaki (Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University)

Speaker Yasuyuki Arai (Department of Cytotherapy, Kyoto University Hospital)

Sponsor Genmab KK, Medical Affairs / AbbVie GK, Medical

MS2-3 Current Status and Future Perspectives of Cellular Immunotherapy for Multiple Myeloma

[No.3 Kobe Portopia Hotel Main Building B1F Kairaku 3]

Chair Emiko Sakaida (Department of Hematology, Chiba University Hospital)

Speaker Junya Kuroda (Kyoto Prefectural University of Medicine Graduate School of Medical Science)

Sponsor Bristol Myers Squibb K.K.

MS2-4 Current Landscape and Challenges in Treating Newly-Diagnosed FLT3-ITD Positive AML

[No.4 Kobe Portopia Hotel Main Building B1F Waraku]

Chair Shunya Arai (Kyorin University School of Medicine, Department of Hematology)

Speaker Takashi Toya (Department of Hematology and Oncology, Dokkyo Medical University)

Sponsor DAIICHI SANKYO COMPANY, LIMITED.

MS2-5 Infectious Complications in Hematologic Malignancies: Addressing Risks Associated with Molecular Targeted Agents and Vaccination

[No.5 Kobe Portopia Hotel South Wing B1F Sapphire]

Chair Yosuke Masamoto (Department of Blood Transfusion, The University of Tokyo Hospital)

Speaker Keiji Okinaka (Division of Infectious Diseases, National Cancer Center Hospital East)

Sponsor BeOne Medicines Japan

MS2-7 Sharing the Future of Hemophilia Care

[No.7 Kobe Portopia Hotel South Wing B1F Emerald]

Chair Takeshi Hagiwara (Department of Blood coagulation, Ogikubo Hospital)

Speaker Yushi Chikasawa (Department of Laboratory Medicine, Tokyo Medical University)

Sponsor Sanofi K.K.

MS2-9 Ruxolitinib for GVHD and PV

[No.9 Kobe International Conference Center 1F Main Hall]

Chair Takanori Teshima (Hokkaido University)

Ruxolitinib, a game-changing strike against GVHD?

Speaker Kazuhiro Ikegame (Hematopoietic Cell Transplantation Center, Aichi Medical University)

Treatment for polycythemia vera

Speaker Kazuya Shimoda (University of Miyazaki, Department of Internal Medicine, Division of Hematology, Diabetes, and Endocrinology)

Sponsor Novartis Pharma K.K.

■MS2-10 The Frontline of Acquired Hemophilia A Treatment

[No.10 Kobe International Conference Center 3F International Conference Room 301]

Chair Teruhisa Fujii (Hemophilia Treatment Center, Hiroshima University Hospital)

New Therapeutic Strategies for Acquired Hemophilia

Speaker Satoshi Higasa (HYOGO MEDICAL UNIVERSITY Respiratory Medicine and Hematology)

Case series: Twelve cases of acquired hemophilia A treated with emicizumab

Speaker Masashi Nishikubo (Kobe City Medical Center General Hospital)

Sponsor CHUGAI PHARMACEUTICAL CO., LTD.

■MS2-11 CMV Infection Control Based on ECIL10 (2025) CMV Guidelines

[No.11 Kobe International Conference Center 4F 401+402]

Chair Naoyuki Uchida (Department of Hematology, Toranomon Hospital)

Speaker Shun-ichi Kimura (Division of Hematology, Jichi Medical University Saitama Medical Center)

Sponsor Takeda Pharmaceutical Company Ltd. Japan Medical Office

■MS2-13 Management and Prevention of COVID-19 in Patients with Hematologic Malignancies – Where are we now ?

[No.13 Kobe International Conference Center 5F 501]

Chair Yoshinobu Kanda (Division of Hematology, Department of Medicine, Jichi Medical University)

Speaker Brian Y. Hayama (Department of Infectious Diseases, Cancer Institute Hospital of JFCR)

Sponsor Pfizer Japan Inc. Medical Affairs

■MS2-14 The Paradigm Shift in AML Therapy: From Current Practice to Future Horizons

[No.14 Kobe International Conference Center 5F 502]

Chair Satoshi Wakita (Department of Hematology, Nippon Medical School)

Speaker Junichiro Yuda (Department of Hematology and Experimental Therapeutics, National Cancer Center Hospital East)

Sponsor Sumitomo Pharma Co.,Ltd

■MS2-15 Treatment strategy for improvement of prognosis and QOL in relapsed/refractory PTCL

[No.15 Kobe International Conference Center 5F 504+505]

Chair Yasushi Isobe (Department of Medical Oncology, Hematology, and Infectious Diseases, Fukuoka University Hospital)

Speaker Shinya Rai (Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University)

Sponsor Meiji Seika Pharma Co., Ltd.

**■MS2-16 Lead Treatment of Multiple Myeloma with Daratumumab
~Treatment choice of TE~**

[No.16 Kobe International Exhibition Hall No.2 Building 3F 3A Meeting Room]

Chair Hiroyuki Takamatsu (Department of Hematology/Faculty of Transdisciplinary Sciences for Innovation, Institute of Transdisciplinary Sciences for Innovation, Kanazawa University)

Revolutions at the front line treatment for transplant-eligible multiple myeloma: daratumumab-based quadruplet regimen and future directions

Speaker Tomohiko Kamimura (Department of Hematology, Harasanshin Hospital)

Sponsor Johnson & Johnson

■MS2-17 Optimization of real-world CAR-T cell therapy by integrating both immune analyses and clinical networks

[No.17 Kobe International Exhibition Hall No.2 Building 2F 2A Meeting Room]

Chair Yoshiki Akatsuka (Immunology, Nagoya University Graduate School of Medicine)

Speaker Toshiki Ochi (Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine)

Sponsor Gilead Sciences K.K.

**■MS2-18 Immune thrombocytopenia
- the key diagnostic and therapeutic strategy**

[No.18 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall B]

Chair Hirokazu Kashiwagi (Osaka Red Cross Blood Center / Department of Hematology and Oncology, Osaka University Graduate School of Medicine)

Speaker Jun Yamanouchi (Division of Blood Transfusion and Cell Therapy, Ehime University Hospital)

Sponsor ASAHI KASEI Pharma Corporation

12-Oct (Sun) 7 : 30—8 : 15

■MS3-2 Considering 5 regimens of Sarclisa®: Lessons Learned from Clinical Data and Experience

[No.2 Kobe Portopia Hotel Main Building B1F Kairaku 1]

Chair Yoshiaki Kuroda (Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital)

Speaker Shuku Sato (Department of Hematology, Shonan Kamakura General Hospital)

Speaker Hirono Iriuchishima (Department of Clinical Research, NHO Shibukawa Medical Center)

Sponsor Sanofi K.K.

MS3-3 Treatment strategies for DLBCL in the CAR T era; up to date overview

[No.3 Kobe Portopia Hotel Main Building B1F Kairaku 3]

- Chair** Tatsu Shimoyama (Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital)
- Speaker** David Miklos (Blood and Marrow Transplantation and Cellular Therapy, Stanford University)
- Sponsor** Gilead Sciences K.K.

MS3-4 PNH Treatment Update: Shaping the Future of Patient Care

[No.4 Kobe Portopia Hotel Main Building B1F Waraku]

- Chair** Hideaki Nakajima (Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine)
- Speaker** Naoshi Obara (Faculty of Medicine, Department of Medical Sciences, Hematology, University of Tsukuba)
- Sponsor** CHUGAI PHARMACEUTICAL CO., LTD.

MS3-5 Therapeutic Advances in LPL/WM Based on ASPEN Trial: Clinical Implications of Zanubrutinib in Real-World Practice

[No.5 Kobe Portopia Hotel South Wing B1F Sapphire]

- Chair** Naohiro Sekiguchi (Hematology Department, National Hospital Organization. Disaster Medical Center)
- Speaker** Masuho Saburi (Department of Hematology, Oita Prefectural Hospital)
- Sponsor** BeOne Medicines Japan

MS3-6 New Treatment Strategies for Chronic Myeloid Leukemia in China

[No.6 Kobe Portopia Hotel South Wing B1F Topaz]

- Chair** Naoto Takahashi (Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine)
- Speaker** Sujiang Zhang (Ruijin Hospital, Shanghai Jiao Tong University School of Medicine)
- Sponsor** Otsuka Pharmaceutical Co., Ltd. Medical Affairs

MS3-7 TFPI killers in non-replacement therapy for hemophilia

[No.7 Kobe Portopia Hotel South Wing B1F Emerald]

- Chair** Midori Shima (Nara Medical University)
- Speaker** Tadashi Matsushita (Department of Transfusion Medicine Nagoya University Hospital)
- Sponsor** Pfizer Japan Inc.

MS3-8 Treatment Strategy for CD123-positive Myeloid Malignancies: Current Approaches and Future Perspectives

[No.8 Kobe Portopia Hotel South Wing B1F Diamond]

- Chair** Ritsuro Suzuki (Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Shimane University)
- Speaker** Naveen Pemmaraju (Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center)
- Sponsor** Nippon Shinyaku CO.,LTD.

MS3-9 Molecular insights and evolving care in MPNs

[No.9 Kobe International Conference Center 1F Main Hall]

- Chair** Kohshi Ohishi (Mie University Hospital Transfusion Medicine and Cell Therapy)
- Speaker** Kazuhiko Ikeda (Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University School of Medicine)
- Sponsor** Recordati Rare Diseases Japan K.K. Medical Affairs

MS3-10 Clinical Impact and Emerging Challenges After Introducing the Hematopoietic Tumor Panel

[No.10 Kobe International Conference Center 3F International Conference Room 301]

- Chair** Takahiro Maeda (Division of Precision Medicine, Kyushu University Graduate School of Medical Sciences)
- Speaker** Masahiro Onozawa (Department of Hematology, Hokkaido University Hospital)
- Sponsor** Astellas Pharma Inc. Medical Affairs

MS3-11 Current Treatment Strategies for Peripheral T-cell lymphoma

[No.11 Kobe International Conference Center 4F 401+402]

- Chair** Kazuhito Yamamoto (Aichi Cancer Center)
- Speaker** Wataru Munakata (National Cancer Center Hospital)
- Sponsor** Takeda Pharmaceutical Company Limited

MS3-13 The Future of ITP Treatment: Immune modulation-based therapeutic strategies aiming for treatment-free remission.

[No.13 Kobe International Conference Center 5F 501]

- Chair** Masataka Kuwana (Nippon Medical School Graduate School of Medicine, Department of Allergy and Rheumatology)
- Speaker** Hisashi Kato (Department of Hematology and Oncology, The University of Osaka Graduate School of Medicine)
- Sponsor** Novartis Pharma K.K. Medical Affairs

MS3-14 Reconsidering the Role of Carfilzomib in the Immunotherapy Era

[No.14 Kobe International Conference Center 5F 502]

Chair Naoya Mimura (Transfusion Medicine and Cell Therapy, Chiba University Hospital)

Mechanism of Action of Carfilzomib and Its Impact on Immunotherapy

Speaker Daisuke Ogiya (Department of Hematology and Oncology, Tokai University School of Medicine)

The Utility of Carfilzomib from a Clinical Perspective

Speaker Taku Kikuchi (Department of Hematology, Japanese Red Cross Medical Center)

Sponsor ONO PHARMACEUTICAL CO., LTD.

MS3-15 The role of activated FXII in HAE (hereditary angioedema) attacks ~Is activated FXII a key player in blood coagulation~

[No.15 Kobe International Conference Center 5F 504+505]

Chair Norimitsu Inoue (Department of Molecular Genetics, Wakayama Medical University)

Current status and issues in the diagnosis and treatment of hereditary angioedema (HAE)

Speaker Kouhei Yamashita (Department of Hematology, Kyoto University Hospital)

True physiological function of coagulationFXII learning from the mechanism of HAE attacks

Speaker Masahiro Ieko (Department of Nursing, Faculty of Health and Medical Sciences, Sapporo University of Health Sciences)

Sponsor CSL Behring K.K.

MS3-16 Future direction of BTKi inhibitors in CLL

[No.16 Kobe International Exhibition Hall No.2 Building 3F 3A Meeting Room]

Chair Jun Takizawa (Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine)

Speaker Yoshikane Kikushige (Center for Cellular and Molecular Medicine, Kyushu University Hospital)

Sponsor Johnson & Johnson

MS3-17 Antibody–drug conjugates targeting BCMA: Clinical significance and positioning of BLENREP

[No.17 Kobe International Exhibition Hall No.2 Building 2F 2A Meeting Room]

Chair Rikio Suzuki (Tokai University School of Medicine Department of Hematology and Oncology)

Speaker Ichiro Hanamura (Department of Internal Medicine, Department of Hematology, Aichi Medical University)

Sponsor GlaxoSmithKline K.K.

MS3-18 Up-to-Date Management of Fungal Infections in the Field of Hematopoietic Cell Transplantation

[No.18 Kobe International Exhibition Hall No.1 Building 2F Exhibition Hall B]

Chair Takahiro Fukuda (National Cancer Center Hospital Dept. Haematopoietic stem cell transplantation)

Practical Approaches to the Concomitant Use of Molecular-Targeted and Antifungal Drugs

Speaker Mizuki Watanabe (National Cancer Center Hospital Dept. Haematopoietic stem cell transplantation)

Key Considerations for Antifungal Agents During The Hematopoietic Stem Cell Transplantation Period

Speaker Hideaki Fujiwara (Department of Hematology and Oncology, Okayama University Hospital)

Sponsor ASAHI KASEI PHARMA CORPORATION

10-Oct (Fri) 11 : 50—12 : 20

**IS1-2 Next-Gen Oncology:
The Promise of iPSC-Derived Allogeneic Cell Therapy**

[No.2 Kobe Portopia Hotel Main Building B1F Kairaku 1]

Chair Mamiko Sakata-Yanagimoto (Department of Hematology, Institute of Medicine, University of Tsukuba)

Accelerating Innovation to Deliver Truly Accessible, Affordable, and Effective Allogeneic Cell Therapy

Speaker Alex Shih-Min Huang (BeOne Medicines, Cell Therapy)

Sponsor BeOne Medicines Japan

11-Oct (Sat) 10 : 40—11 : 10

IS2-2 A Paradigm Shift in Paroxysmal Nocturnal Hemoglobinuria (PNH) Management: Achieving Control of Intravascular and Extravascular Hemolysis

[No.2 Kobe Portopia Hotel Main Building B1F Kairaku 1]

Chair Hiroki Yamaguchi (Department of Hematology, Nippon Medical School)

Speaker Masatoshi Sakurai (Division of Hematology, Department of Medicine, Keio University School of Medicine)

Sponsor Medical Affairs Division, Alexion Pharma G.K.